Alice Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alice Wang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- William Damsky
Department of Dermatology, Yale School of Medicine , New Haven, CT
7 shared publications - Brett King
Yale School of Medicine New Haven Connecticut USA
4 shared publications - Christine J. Ko
Department of Dermatology Yale School of Medicine New Haven Connecticut USA
3 shared publications A. Galan
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
2 shared publicationsA. Zubek
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
2 shared publicationsB. King
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
2 shared publications
Latest Publications
- Top Cited Papers
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
A dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
Top Cited PapersA dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- Open Access
- 9 February 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100189
IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
- 9 February 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100189
Open AccessIL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
- Open Access
- 5 August 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (2) , 214-218
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Leukoderma, or hypomelanosis of the skin, can occur in response to various chemical and pharmacologic substances ranging from topical medications to optic preparations and systemic medications. In this case report, we present a 78-year-old man with a history of restless leg syndrome (RLS) who had been using rotigotine transdermal patches once daily for 1 year and developed leukoderma on the bilateral anterior shoulders in the area of patch application. Histopathologic examination showed an absence of melanocytes at the dermal-epidermal junction confirmed by Melan A stain. While the patient was not bothered by the depigmentation and elected to continue the rotigotine patch for his RLS, this case highlights leukoderma as a potential side effect of dopamine transdermal patches and offers insight into the potential mechanism of hypopigmentation in response to dopamine agonism.
- 5 August 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (2) , 214-218
Open AccessLeukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Leukoderma, or hypomelanosis of the skin, can occur in response to various chemical and pharmacologic substances ranging from topical medications to optic preparations and systemic medications. In this case report, we present a 78-year-old man with a history of restless leg syndrome (RLS) who had been using rotigotine transdermal patches once daily for 1 year and developed leukoderma on the bilateral anterior shoulders in the area of patch application. Histopathologic examination showed an absence of melanocytes at the dermal-epidermal junction confirmed by Melan A stain. While the patient was not bothered by the depigmentation and elected to continue the rotigotine patch for his RLS, this case highlights leukoderma as a potential side effect of dopamine transdermal patches and offers insight into the potential mechanism of hypopigmentation in response to dopamine agonism.
- Open Access
- 7 May 2021
- Published by Elsevier in JID Innovations
- Vol. 1 (2) , 100021
Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis
- 7 May 2021
- Published by Elsevier in JID Innovations
- Vol. 1 (2) , 100021
Open AccessCytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis
- Open Access
- 1 January 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 7, 122-124
Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy
- 1 January 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 7, 122-124
Open AccessTreatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy
- 1 July 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (7) , 1446-1449.e4
Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea
- 1 July 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (7) , 1446-1449.e4
Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea
- 1 June 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (6) , 1708-1710.e2
Treatment of severe lichen planus with the JAK inhibitor tofacitinib
- 1 June 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (6) , 1708-1710.e2
Treatment of severe lichen planus with the JAK inhibitor tofacitinib
- 11 April 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (10) , E583-E585
Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis
Interleukin (IL) – 17 inhibitors are increasingly used to treat psoriasis and psoriatic arthritis (PsA). There are presently three approved IL‐17 inhibitors: ixekizumab and secukinumab block IL‐17A while brodalumab targets IL‐17Rα (IL‐17 receptor). Therapeutic monoclonal antibodies are known to occasionally paradoxically induce inflammatory diseases through poorly understood mechanism(s). Perhaps the most well‐known example is TNF‐α inhibitor induced psoriasis. Here we describe three patients that developed or had worsening of sarcoidosis while taking an IL‐17 inhibitor.
- 11 April 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (10) , E583-E585
Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis
Interleukin (IL) – 17 inhibitors are increasingly used to treat psoriasis and psoriatic arthritis (PsA). There are presently three approved IL‐17 inhibitors: ixekizumab and secukinumab block IL‐17A while brodalumab targets IL‐17Rα (IL‐17 receptor). Therapeutic monoclonal antibodies are known to occasionally paradoxically induce inflammatory diseases through poorly understood mechanism(s). Perhaps the most well‐known example is TNF‐α inhibitor induced psoriasis. Here we describe three patients that developed or had worsening of sarcoidosis while taking an IL‐17 inhibitor.
- 6 April 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9) , E497-E499
Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis
- 6 April 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9) , E497-E499
Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis